Clinical Trial Update: Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) [Phase 2]

View source ↗

Summary

A Phase 2 trial update is reported for apatinib in treating recurrent or metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN